oxiconazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| systemic antifungal agents, miconazole derivatives | 3408 | 64211-45-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 30, 1988 | FDA | FOUGERA PHARMS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D01AC11 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Imidazole and triazole derivatives |
| ATC | G01AF17 | GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Imidazole derivatives |
| FDA CS | M0002083 | Azoles |
| FDA EPC | N0000175487 | Azole Antifungal |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000935 | Antifungal Agents |
| CHEBI has role | CHEBI:35441 | antiinfective agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Tinea pedis | indication | 6020002 | DOID:12403 |
| Pityriasis versicolor | indication | 56454009 | DOID:9060 |
| Tinea corporis | indication | 84849002 | |
| Tinea cruris | indication | 399029005 | |
| Skin irritation | contraindication | 367466007 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.02 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Alpha-2A adrenergic receptor | GPCR | Ki | 5.82 | DRUG MATRIX | |||||
| Cytochrome P450 3A4 | Enzyme | IC50 | 7.05 | DRUG MATRIX | |||||
| Sodium-dependent serotonin transporter | Transporter | Ki | 6.37 | DRUG MATRIX | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.72 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.50 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.93 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.53 | DRUG MATRIX | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 5.78 | DRUG MATRIX | |||||
| D(3) dopamine receptor | GPCR | Ki | 6.17 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 5.94 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 6.02 | DRUG MATRIX | |||||
| Beta-3 adrenergic receptor | GPCR | Ki | 5.45 | DRUG MATRIX | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 6.22 | DRUG MATRIX | |||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 5.68 | DRUG MATRIX | |||||
| Cytochrome P450 2D6 | Enzyme | IC50 | 6 | DRUG MATRIX | |||||
| Adenosine receptor A3 | GPCR | Ki | 6.45 | DRUG MATRIX | |||||
| Delta-type opioid receptor | GPCR | Ki | 5.73 | DRUG MATRIX | |||||
| Acetylcholinesterase | Enzyme | IC50 | 5.33 | DRUG MATRIX | |||||
| Cytochrome P450 2C9 | Enzyme | IC50 | 5.52 | DRUG MATRIX | |||||
| Cytochrome P450 2C19 | Enzyme | IC50 | 7.40 | DRUG MATRIX | |||||
| Thromboxane-A synthase | Enzyme | IC50 | 6.21 | DRUG MATRIX | |||||
| Indoleamine 2,3-dioxygenase 1 | Enzyme | IC50 | 4.55 | CHEMBL | |||||
| Substance-K receptor | GPCR | Ki | 5.97 | DRUG MATRIX | |||||
| D(1A) dopamine receptor | GPCR | Ki | 5.68 | DRUG MATRIX | |||||
| Lanosterol 14-alpha demethylase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | IC50 | 5.25 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019474 | VUID |
| N0000147594 | NUI |
| D00885 | KEGG_DRUG |
| 64211-46-7 | SECONDARY_CAS_RN |
| 4019474 | VANDF |
| C0069765 | UMLSCUI |
| CHEBI:7825 | CHEBI |
| CHEMBL1262 | ChEMBL_ID |
| CHEMBL1200836 | ChEMBL_ID |
| DB00239 | DRUGBANK_ID |
| C022155 | MESH_SUPPLEMENTAL_RECORD_UI |
| 5353853 | PUBCHEM_CID |
| 4729 | INN_ID |
| C668Q9I33J | UNII |
| 32638 | RXNORM |
| 239524 | MMSL |
| 5212 | MMSL |
| 002932 | NDDF |
| 004963 | NDDF |
| 372778004 | SNOMEDCT_US |
| 41067005 | SNOMEDCT_US |
| 57263002 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Oxiconazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0168-0358 | CREAM | 10 mg | TOPICAL | NDA authorized generic | 22 sections |
| Oxistat | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10337-358 | CREAM | 10 mg | TOPICAL | NDA | 22 sections |
| Oxistat | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10337-359 | LOTION | 10 mg | TOPICAL | NDA | 22 sections |
| Oxistat | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-459 | LOTION | 30 mg | TOPICAL | NDA | 22 sections |
| Oxiconazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-1359 | CREAM | 10 mg | TOPICAL | ANDA | 25 sections |
| Oxistat | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62559-285 | LOTION | 10 mg | TOPICAL | NDA | 23 sections |